Literature DB >> 8970534

One-day protocol for cerebral perfusion reserve with acetazolamide.

N Hattori1, Y Yonekura, F Tanaka, T Fujita, J Wang, K Ishizu, H Okazawa, N Tamaki, J Konishi.   

Abstract

UNLABELLED: A one-day protocol with a double injection of 99mTc-ECD was introduced for the assessment of cerebral perfusion reserve with acetazolamide (ACZ). The purpose of this study was to investigate the feasibility and effectiveness of this protocol.
METHODS: Thirty subjects were given double injections of 99mTc-ECD (first dose 370 MBq; second dose 740 MBq) for consecutive brain perfusion studies. Serial dynamic SPECT scans (1 min x 50 frames) were performed with the first set of SPECT data obtained by totaling the data for the frames taken between 5 and 20 min, and the second by subtracting the decay and dose-corrected initial SPECT data from the sum of the data obtained between 35 and 50 min. To evaluate the feasibility and effectiveness of the procedure, 23 of the 30 subjects were injected with ACZ 14 min after the first dose. To evaluate the reproducibility, seven subjects were not given the ACZ. The washout rate (WR) was calculated for three stages (WR1 = from 6 to 14 min, WR2 = from 20 to 28 min, and WR3 = from 36 to 44 min). Regional count increase (percent increase) and the percent count difference between normal and affected side (percent difference) were also calculated.
RESULTS: Values for WR1, WR2 and WR3 did not show significant differences among the stages (WR1 = -1.43% +/- 6.09%, WR2 = -0.65% +/- 6.57%, and WR3 = -1.60% +/- 4.28%; F-value = 0.33, p-value = 0.72). Reproducibility was excellent (second SPECT = 0.964 x first SPECT; r = 0.997). Mean count increase after ACZ was 21.7%. In patients with unilateral cerebrovascular disease, the percent increase after ACZ loading was significantly greater on the normal side (26.6% +/- 13.0%) than on the affected side (19.3% +/- 13.2%) (p < 0.01), resulting in a significant increase in percent difference (control: 14.3% +/- 10.7%, ACZ: 19.2% +/- 11.5%; p < 0.01).
CONCLUSION: ECD washout was minimal during the first 50 min after injection and was not affected by ACZ, which supports the feasibility of this protocol. The simple procedure and short acquisition time of this method renders it clinically useful for measuring cerebral perfusion reserve.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970534

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

1.  A study of the acute effect of smoking on cerebral blood flow using 99mTc-ECD SPET.

Authors:  Yuka Yamamoto; Yoshihiro Nishiyama; Toshihide Monden; Katashi Satoh; Motoomi Ohkawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-15       Impact factor: 9.236

2.  A comparative study of perfusion CT and 99m Tc-HMPAO SPECT measurement to assess cerebrovascular reserve capacity in patients with internal carotid artery occlusion.

Authors:  Sven O Eicker; B Turowski; H-J Heiroth; H-J Steiger; D Hänggi
Journal:  Eur J Med Res       Date:  2011-11-10       Impact factor: 2.175

3.  Improvement of signal-to-noise ratio using iterative reconstruction in a 99m Tc-ECD split-dose injection protocol.

Authors:  Takashi Yokoi; Hiroyuki Shinohara; Akihiro Takaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-24       Impact factor: 9.236

Review 4.  Basal and Acetazolamide Brain Perfusion SPECT in Internal Carotid Artery Stenosis.

Authors:  Teck Huat Wong; Qaid Ahmed Shagera; Hyun Gee Ryoo; Seunggyun Ha; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2020-01-08

5.  Perfusion Study for Internal Carotid Artery Trapping of a Traumatic Pseudoaneurysm in an Unconscious Patient.

Authors:  Seong-Jong Lee; Sun-Chul Hwang; Jung-Mi Park; Bum-Tae Kim
Journal:  Korean J Neurotrauma       Date:  2015-10-31

6.  Neural Correlates of Motor Recovery Measured by SPECT at Six Months After Basal Ganglia Stroke.

Authors:  Ji Won Choi; Myoung Hyoun Kim; Soon-Ah Park; Deok Su Sin; Min-Su Kim
Journal:  Ann Rehabil Med       Date:  2017-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.